TRML241220P17500
- 0.55
- 0.000.00%
Tourmaline Bio Newsroom
Tourmaline Bio, Inc. Announces Virtual Investor Day to Discuss Development of Pacibekitug on December 10, 2024
H.C. Wainwright Maintains Tourmaline Bio(TRML.US) With Buy Rating, Raises Target Price to $49
Tourmaline Bio Price Target Raised to $49 From $48 at H.C. Wainwright
Tourmaline Bio's Promising Clinical Developments and Financial Stability Underpin Buy Rating
Express News | Tourmaline Bio Inc Files for Mixed Shelf of up to $350 Mln - SEC Filing
Talaris Therapeutics GAAP EPS of -$0.78 Beats by $0.05
Tourmaline Bio | 10-Q: Q3 2024 Earnings Report
Tourmaline Bio Reports Q3 EPS (78c), Consensus (82c)
Tourmaline Bio | 8-K: Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Tourmaline Bio 3Q Loss/Shr 78c >TRML
Press Release: Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Tourmaline Bio: Unlocking Value Through Promising IL-6 Inhibition Strategy in ASCVD Treatment
Cantor Fitzgerald Initiates Tourmaline Bio(TRML.US) With Buy Rating
Cantor Fitzgerald Initiates Tourmaline Bio at Overweight
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease With Dr. Dipender Gill on Friday, November 1, 2024
Tourmaline Bio Management to Meet With Truist
Guggenheim Maintains Tourmaline Bio(TRML.US) With Buy Rating
Tourmaline Bio Stock Slides 7% Amid News of CMO's Departure
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
Tourmaline Bio's Chief Medical Officer Resigns Amicably